We track the innovations reshaping cancer diagnosis, treatment and care — and ask the question that matters most: can health systems actually deliver them, fairly, to the people who need them? Trustworthy information and practical tools, in one place.
We follow the full arc of cancer innovation — and the systems that must absorb it. The through-line is always access: what can and should systems do to improve outcomes and avoid inequities.
Molecular diagnostics, targeted drugs, cell therapies, cancer vaccines, screening, imaging, surgery and radiation — reviewed for what they mean in practice.
Who can reach these therapies, and who is left behind. We take a health-systems view of financing, capacity and fairness.
Doing less where less is enough. We spotlight evidence for safely dialling back treatment to reduce harm, cost and over-treatment.
Innovation only counts if it moves the needle at scale. We connect new technology to real-world system performance.
Beyond commentary — we build and share open tools to help teams organise, assess and improve cancer care.
Independent, transparent, and referenced. We exist to be a source you can rely on in a noisy information landscape.
A referenced global roundup — policy, access, technology, drugs and pricing, and low- and middle-income settings — checked against primary sources. New each week; the full archive stays open.
Open, practical instruments to help clinicians, planners and policymakers organise and deliver cancer care. A selection in development below.
Direct medical and wider societal costs across tumour streams, worldwide.
Visualise disparities in access to cancer therapies across regions and populations.
Project the future economic burden of cancer to inform policy and planning.
One trustworthy, referenced read on cancer innovation and access — delivered every week. Built for people who plan, fund and deliver cancer care.